Martin Allen-Auerbach
· ProfessorVerifiedUniversity of California, Los Angeles · Nuclear Medicine & Theranostics
Active 1999–2026
About
Martin Allen-Auerbach is a professor in the Pharmacology Department at the University of California, Los Angeles. His clinical research focuses on investigating the role of PET/CT in oncology, particularly its application in improving disease diagnosis, staging, and monitoring of treatment. More recently, he has been involved in researching new PET tracers with an emphasis on non-invasive molecular profiling of neuroendocrine tumors, as well as exploring targeted therapies for neuroendocrine tumors and prostate cancer.
Research topics
- Medicine
- Internal medicine
- Pathology
- Nuclear medicine
- Computer Science
- Oncology
- Urology
- Computer Security
- Political Science
- Emergency medicine
- Virology
- Engineering ethics
- Engineering
- Radiology
- Intensive care medicine
- Surgery
- Medical emergency
- Medical physics
- Law
Selected publications
[ <sup>68</sup> Ga]Ga-FAPI-46 PET/CT in Adrenocortical Neoplasm, Oncocytic Type
Journal of Nuclear Medicine · 2026-03-26
articleAdrenocortical neoplasm, oncocytic type (ACNO), known as adrenal oncocytoma, is a rare histologic subtype of adrenocortical neoplasms. Approximately one third of ACNOs are benign, 40% are borderline, and one fourth are malignant ([1][1]). Although benign and borderline ACNOs have a favorable
International Journal of Radiation Oncology*Biology*Physics · 2025-09-01 · 3 citations
article2025-12-11
articleOpen access<p>PET scans taken for all patients treated with CART19/20 cell therapy.</p>
Journal of Clinical Oncology · 2025-05-28
articleTPS5110 Background: The phase III VISION trial demonstrated that 177 Lu-PSMA-617 radioligand therapy (RLT) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy and at least one androgen receptor pathway inhibitor (ARPI). As a result, 177 Lu-PSMA-617 therapy has been approved in this patient population by the U.S. Food and Drug Administration for up to six cycles (7.4 GBq per cycle) every 6 weeks. Unfortunately, this treatment is not curative and patients relapse even after initially favorable responses. When this occurs, patients have limited treatment options given they have had prior chemotherapy and ARPI regimens. Re-administration of 177 Lu-PSMA-617 in patients who previously benefited from therapy and had limited toxicity seems to be a promising option. Small retrospective studies have reported favorable outcomes. Further prospective data with larger sample sizes are needed to confirm these findings. Methods: RE-LuPSMA is an investigator-initiated, single-arm, single-center, open-label, phase 2 clinical trial (NCT06288113). This study plans to enroll 40 patients with progressive mCRPC who previously completed 4-6 cycles of 177 Lu-PSMA-617 therapy with a favorable response. Favorable response is defined as a prostate-specific antigen (PSA) decline ≥50% during the first regimen. Progression following the first regimen is defined using imaging or PSA (two consecutive PSA increases ≥3 weeks apart). Patients who received another line of prostate cancer therapy within two months of completing the first regimen of 177 Lu-PSMA-617 are excluded. Patients must meet PSMA PET/CT VISION criteria. PSMA PET/CT must have been completed within 8 weeks of the planned first cycle of re-challenge therapy. Upon enrollment, participants will receive up to 6 additional cycles of 177 Lu-PSMA-617 (7.4GBq every 6 weeks). Patients will follow-up every 6 months until 2 years from the end of re-challenge therapy. The primary endpoint is 12-month OS measured from the start of re-challenge therapy. The study will have 80% power to detect a difference between the null hypothesis of 50% and the study hypothesis of 71%. Secondary endpoints include adverse event rates, PSA response rates (proportion of patients with a PSA decrease of ≥50%), biochemical progression-free survival (time until PSA level increases 25% and 2 ng/mL above the nadir), radiographic progression-free survival, and health-related quality of life changes (measured using Functional Assessment of Cancer Therapy - Radionuclide Therapy [FACT-RNT] and Brief Pain Inventory [Short Form]). Enrollment has started with a planned study duration of 4 years of which subject accrual occurs in the first 12 months. Clinical trial information: NCT06288113 .
2025-12-11
articleOpen access<p>Representativeness of study participants</p>
2025-12-11
articleOpen access<p>Patient 009 exhibited elevated cytokine, C-reactive protein, and ferritin levels prior to and after CART19/20 cell infusion. (A) Serum levels of various cytokines measured by Luminex multiplex assay. (B) C-reactive protein (CRP) levels for Patient 009 (left-most) and all patients (second from left). Peak and median CRP levels are shown in box-and-whisker plots. (C) Ferritin levels for Patient 009 (left-most) and all patients (second from left). Peak and median ferritin levels are shown in box-and-whisker plots.</p>
Nuklearmedizin - NuclearMedicine · 2025-03-01
article2025-12-11
articleOpen access<p>Flow-cytometry analysis of post-infusion peripheral blood samples. (A) Gating strategy for T-cell analysis in CART19/20 cell products and post-infusion patient peripheral mononuclear blood cells (PBMCs). Two viable gates were set based on side scatter (SSC-A) vs. forward scatter (FSC-A). The more restrictive “Viable” gate includes only viable lymphocytes, to enable more precise identification of T cells. The “Viable (inclusive)” gate includes all viable PBMCs, to enable calculation of CAR-T cells as a fraction of PBMCs. Truncated epidermal growth factor receptor (EGFRt) is co-expressed with the CAR, and EGFRt staining is used for CAR expression detection. Percent CAR+ T cells among viable singlets as shown in main-text Fig. 4b is the EGFRt+ population as a % of grandparent in the viable PBMC branch.Percent CAR expression among T cells as shown in main-text Fig. 4c is the EGFRt+ population as a % of parent in the viable lymphocyte branch. (B) Examples of post-infusion patient sample analysis.</p>
2025-12-11
articleOpen access<p>Comparison of CART19/20 cell therapy results with reported data from trials evaluating other CD19/CD20 bispecific CAR-T cell therapies and commercially available CD19 CAR-T cell therapies.</p>
Beyond the Prostate: Incidental Detection of Male Breast Carcinoma on [ <sup>18</sup> F]DCFPyl
Journal of Nuclear Medicine · 2025-12-18
articleOpen accessSenior authorProstate-specific membrane antigen (PSMA) is consistently expressed in tumor neovasculature but variably in tumor cells, with prior reports demonstrating PSMA uptake in invasive ductal carcinoma in men ([1][1]). This case reinforces the value of PSMA in characterizing breast cancer in men,
Frequent coauthors
- 89 shared
Johannes Czernin
- 51 shared
Jérémie Calais
Molecular Theranostics (United States)
- 45 shared
Ken Herrmann
- 37 shared
Matthias Benz
Deutschen Konsortium für Translationale Krebsforschung
- 30 shared
Antoni Ribas
Parker Institute for Cancer Immunotherapy
- 30 shared
Pawan Gupta
Academy of Scientific and Innovative Research
- 27 shared
Yvonne Y. Chen
University of California, Los Angeles
- 27 shared
Sven de Vos
University of California, Los Angeles
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Martin Allen-Auerbach
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup